Nebivolol for the treatment of heart failure

Bibliography

• Hunt SA, Abraham WT, Chin MH, 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;20:e391-479
   Google Scholar
• Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970 – 1974 and 1990 – 1994. Circulation 2006;113:799-805
   PubMed Web of Science ®Google Scholar
• Mosterd A, Hoes AW, de Bruyne MC, Prevalence of heart failure and left ventricular dysfunction in the general population; the Rotterdam study. Eur Heart J 1999;20:447-55
   PubMed Web of Science ®Google Scholar
• Triposkiadis F, Karayannis G, Giamouzis G, The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009;54:1747-62
   PubMed Web of Science ®Google Scholar
• Longhini C, Molino C, Fabbian F. Cardiorenal syndrome: still not a defined entity. Clin Exp Nephrol 2010;14:12-21
   PubMed Web of Science ®Google Scholar
• Grassi G, Seravalle G, Quarti-Trevano F. The 'neuroadrenergic hypothesis' in hypertension: current evidence. Exp Physiol 2010;95:581-6
   PubMed Web of Science ®Google Scholar
• Ursino MG, Vasina V, Raschi E, The beta3-adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res 2009;59:221-34
   PubMed Web of Science ®Google Scholar
• Gauthier C, Seze-Goismier C, Rozec B. Beta 3-adrenoceptors in the cardiovascular system. Clin Hemorheol Microcirc 2007;37:193-204
   PubMed Web of Science ®Google Scholar
• Satwani S, Dec GW, Narula J. Beta-adrenergic blockers in heart failure: review of mechanisms of action and clinical outcomes. J Cardiovasc Pharmacol Ther 2004;9:243-55
   PubMed Web of Science ®Google Scholar
• The Cardiac Insufficiency Bisoprolol Study. II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13
   PubMed Web of Science ®Google Scholar
• Hjalmarson A, Goldstein S, Fagerberg B, for the MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA 2000;283:1295-302
   PubMed Web of Science ®Google Scholar
• Packer M, Fowler MB, Roecker EB, for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-9
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Swedberg K, Cleland JG, for the COMET investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13
   PubMed Web of Science ®Google Scholar
• Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67
   PubMed Web of Science ®Google Scholar
• Dickstein K, Cohen-Solal A, Filippatos G, ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-442
   PubMed Web of Science ®Google Scholar
• Pauwels PJ, Gommeren W, Van Lommen G, The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Mol Pharmacol 1988;34:843-51
   PubMed Web of Science ®Google Scholar
• Van Nueten L, De Cree J. Nebivolol: comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure. Cardiovasc Drugs Ther 1998;12:339-44
   PubMed Web of Science ®Google Scholar
• Brixius K, Bundkirchen A, Bolck B, Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol 2001;133:1330-8
   PubMed Web of Science ®Google Scholar
• Bundkirchen A, Brixius K, Bolck B, Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies. Eur J Pharmacol 2003;460:19-26
   PubMed Web of Science ®Google Scholar
• Cockcroft JR, Chowienczyk PJ, Brett SE, Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995;274:1067-71
   PubMed Web of Science ®Google Scholar
• Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994;38:199-204
   PubMed Web of Science ®Google Scholar
• Dessy C, Saliez J, Ghisdal P, Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005;112:1198-205
   PubMed Web of Science ®Google Scholar
• Broeders MA, Doevendans PA, Bekkers BC, Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation 2000;102:677-84
   PubMed Web of Science ®Google Scholar
• Evangelista S, Garbin U, Pasini AF, Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells. Pharmacol Res 2007;55:303-9
   PubMed Web of Science ®Google Scholar
• de Groot AA, Mathy MJ, van Zwieten PA, Peters SL. Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol 2004;43:148-53
   PubMed Web of Science ®Google Scholar
• Sharma R, Davidoff MN. Oxidative stress and endothelial dysfunction in heart failure. Congest Heart Fail 2002;8:165-72
   PubMedGoogle Scholar
• Van de Water A, Janssens W, Van Neuten J, Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol 1988;11:552-63
   PubMed Web of Science ®Google Scholar
• Paulus WJ, Shah AM. NO and cardiac diastolic function. Cardiovasc Res 1999;43:595-606
   PubMed Web of Science ®Google Scholar
• Brehm BR, Wolf SC, Bertsch D, Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 2001;49:430-9
   PubMed Web of Science ®Google Scholar
• Wolf SC, Sauter G, Preyer M, Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol. Cell Physiol Biochem 2007;19:129-36
   PubMed Web of Science ®Google Scholar
• Wolf SC, Sauter G, Jobst J, Major differences in gene expression in human coronary smooth muscle cells after nebivolol or metoprolol treatment. Int J Cardiol 2008;125:4-10
   PubMed Web of Science ®Google Scholar
• Kuroedov A, Cosentino F, Luscher TF. Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. Cardiovasc Drug Rev 2004;22:155-68
   PubMed Web of Science ®Google Scholar
• Falciani M, Rinaldi B, D'Agostino B, Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol 2001;38:922-9
   PubMed Web of Science ®Google Scholar
• Celik T, Yuksel UC, Iyisoy A, Effects of nebivolol on platelet activation in hypertensive patients: a comparative study with metoprolol. Int J Cardiol 2007;116:206-11
   PubMed Web of Science ®Google Scholar
• Van Peer A, Snoeck E, Woestenborghs R, Clinical pharmacokinetics of nebivolol. A review. Drug Investig 1991;3:25-30
   Google Scholar
• Mangrella M, Rossi F, Fici F, Rossi F. Pharmacology of nebivolol. Pharmacol Res 1998;38:419-31
   PubMed Web of Science ®Google Scholar
• Gu Z, Robinson RA, Cai L, Metabolism study of 14C-nebivolol in humans with different CYP2D6 genotypes. Paper presented at: American Association of Pharmaceutical Scientists Annual Meeting and Exposition; 26 – 30 October 2003; Salt Lake City, UT
   Google Scholar
• Lefebvre J, Poirier L, Poirier P, The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br J Clin Pharmacol 2007;63:575-82
   PubMed Web of Science ®Google Scholar
• Cheymol G, Woestenborghs R, Snoeck E, Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol 1997;51:493-8
   PubMed Web of Science ®Google Scholar
• Shaw AA, Liu S, Tu HC, Effects of hepatic impairment on the pharmacokinetic disposition of nebivolol: a dual acting nitric oxide modulating/cardioselective beta1-antagonist. Clin Pharmacol Ther 2005;77:P41
   Web of Science ®Google Scholar
• Shaw AA, Liu S, Zachwieja LF, Effects of varying degrees of renal impairment on the pharmacokinetic disposition of nebivolol. Clin Pharmacol Ther 2005;77:P38
   Web of Science ®Google Scholar
• Kamali F, Howes A, Thomas SH, A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. Br J Clin Pharmacol 1997;43:201-4
   PubMed Web of Science ®Google Scholar
• Lindamood C, Ortiz S, Shaw A, Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies. J Clin Pharmacol 2011;51:575-85
   PubMed Web of Science ®Google Scholar
• A.Menarini Pharmaceuticals UK. Nebilet 5 mg tablets: summary of product characteristics. Available from: http://www.medicines.org.uk/EMC/medicine/9145/SPC/Nebilet+5mg+Tablets/ [Last accessed 10 September 2011]
   Google Scholar
• Bystolic (nebivolol) tablets: prescribing information. Available from: http://www.frx.com/pi/bystolic_pi.pdf [Last accessed 12 September 2011]
   Google Scholar
• Cazzola M, Matera MG, Ruggeri P, Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD. Respiration 2004;71:159-64
   PubMed Web of Science ®Google Scholar
• Cheng JW. Nebivolol: a third-generation beta-blocker for hypertension. Clin Ther 2009;31:447-62
   PubMed Web of Science ®Google Scholar
• Brixius K, Middeke M, Lichtenthal A, Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 2007;34:327-31
   PubMed Web of Science ®Google Scholar
• Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998;11:1258-65
   PubMed Web of Science ®Google Scholar
• Pischon T, Sharma AM. Use of beta-blockers in obesity hypertension: potential role of weight gain. Obes Rev 2001;2:275-80
   PubMedGoogle Scholar
• Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007;67:1097-107
   PubMed Web of Science ®Google Scholar
• Gielen W, Cleophas TJ, Agrawal R. Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther 2006;44:344-57
   PubMed Web of Science ®Google Scholar
• De Cree J, Geukens H, Cobo C, Verhaegen H. Subacute hemodynamic effects of nebivolol in man at rest and during exercise. Angiology 1987;38:440-8
   PubMed Web of Science ®Google Scholar
• De Cree J, Franken P, Vandevivere J, Hemodynamic effects of nebivolol in men: comparison of radionuclide angiocardiography with systolic time intervals. Angiology 1988;39:526-34
   PubMed Web of Science ®Google Scholar
• De Cree J, Cobo C, Geukens H, Verhaegen H. Comparison of the subacute hemodynamic effects of atenolol, propranolol, pindolol, and nebivolol. Angiology 1990;41:95-105
   PubMed Web of Science ®Google Scholar
• De Cree J, Van Nueten L, Geukens H, Verhaegen H. Comparative cardiac haemodynamics of bisoprolol, celiprolol, carvedilol and nebivolol in normal volunteers. Int J Clin Pharmacol Res 1992;12:159-63
   PubMedGoogle Scholar
• Brune S, Schmidt T, Tebbe U, Kreuzer H. Hemodynamic effects of nebivolol at rest and on exertion in patients with heart failure. Angiology 1990;41:696-701
   PubMed Web of Science ®Google Scholar
• Lechat P, Boutelant S, Komajda M, Pilot study of cardiovascular effects of nebivolol in congestive heart failure. Drug Investig 1991;3:69-81
   Google Scholar
• Wisenbaugh T, Katz I, Davis J, Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993;21:1094-100
   PubMed Web of Science ®Google Scholar
• Uhlir O, Dvorak I, Gregor P, Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial. J Card Fail 1997;3:271-6
   PubMedGoogle Scholar
• Brehm BR, Wolf SC, Gorner S, Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study. Eur J Heart Fail 2002;4:757-63
   PubMed Web of Science ®Google Scholar
• Patrianakos AP, Parthenakis FI, Mavrakis HE, Effects of Nebivolol on left ventricular function and exercise capacity in patients with non-ischaemic dilated cardiomyopathy. A randomised placebo-controlled study. Hellenic J Cardiol 2005;46:199-207
   PubMedGoogle Scholar
• Erdogan D, Gullu H, Caliskan M, Nebivolol improves coronary flow reserve in patients with idiopathic dilated cardiomyopathy. Heart 2007;93:319-24
   PubMed Web of Science ®Google Scholar
• Edes I, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail 2005;7:631-9
   PubMed Web of Science ®Google Scholar
• Rousseau MF, Chapelle F, Van Eyll C, Medium-term effects of beta-blockade on left ventricular mechanics: a double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. J Card Fail 1996;2:15-23
   PubMedGoogle Scholar
• Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail 2003;5:621-7
   PubMed Web of Science ®Google Scholar
• Patrianakos AP, Parthenakis FI, Mavrakis HE, Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study. Am Heart J 2005;150:985- e9-18
   PubMed Web of Science ®Google Scholar
• Lombardo RM, Reina C, Abrignani MG, Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. Am J Cardiovasc Drugs 2006;6:259-63
   PubMedGoogle Scholar
• Marazzi G, Volterrani M, Caminiti G, Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients. J Card Fail 2011;17:703-9
   PubMed Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJ, on behalf of the SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25
   PubMed Web of Science ®Google Scholar
• Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001;3:351-7
   PubMed Web of Science ®Google Scholar
• Nasr IA, Bouzamondo A, Hulot JS, Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007;28:457-62
   PubMed Web of Science ®Google Scholar
• Ghio S, Magrini G, Serio A, on behalf of the SENIORS investigators. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 2006;27:562-8
   PubMed Web of Science ®Google Scholar
• van Veldhuisen DJ, Cohen-Solal A, Bohm M, on behalf of the SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009;53:2150-8
   PubMed Web of Science ®Google Scholar
• Ambrosio G, Flather MD, Bohm M, beta-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure. Heart 2011;97:209-14
   PubMed Web of Science ®Google Scholar
• Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 2001;33:1897-918
   PubMed Web of Science ®Google Scholar
• Dobre D, van Veldhuisen DJ, Mordenti G, on behalf of the SENIORS Investigators. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. Am Heart J 2007;154:109-15
   PubMed Web of Science ®Google Scholar
• Cohen-Solal A, Kotecha D, van Veldhuisen DJ, on behalf of the SENIORS Investigators. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail 2009;11:872-80
   PubMed Web of Science ®Google Scholar
• de Boer RA, Doehner W, van der Horst IC, on behalf of the SENIORS Investigators. Influence of diabetes mellitus and hyperglycemia on prognosis in patients > or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). Am J Cardiol 2010;106:78-86; e1
   PubMed Web of Science ®Google Scholar
• Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 2001;1:181-93
   PubMedGoogle Scholar
• Palazzuoli A, Antonelli G, Nuti R. Anemia in Cardio-Renal Syndrome: clinical impact and pathophysiologic mechanisms. Heart Fail Rev 2011;16:603-7
   PubMed Web of Science ®Google Scholar
• von Haehling S, van Veldhuisen DJ, Roughton M, Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. Eur J Heart Fail 2011;13:656-63
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536
   PubMed Web of Science ®Google Scholar
• Predel HG, Mainka W, Schillings W, Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension. J Hum Hypertens 2001;15:715-21
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Meeting of the Cardiovascular and Renal Drugs Advisory Committee. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM199554.pdf [Last accessed 9 July 2011]
   Google Scholar
• Dulin BR, Haas SJ, Abraham WT, Krum H. Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials. Am J Cardiol 2005;95:896-8
   PubMed Web of Science ®Google Scholar
• Bhatia RS, Tu JV, Lee DS, Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-9
   PubMed Web of Science ®Google Scholar
• Hermans MP, De Coster O, Seidel L, Quality of life and efficacy of nebivolol in an open-label study in hypertensive patients. The QoLaN study. Blood Press 2009;18:5-14
   Web of Science ®Google Scholar
• Mason RP, Kalinowski L, Jacob RF, Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 2005;112:3795-801
   PubMed Web of Science ®Google Scholar